Slide 1: Investor Relations, August 1, 2024
Investor Relations August 1, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2024 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Omnicell Investment Highlights
Investor Relations – August 1, 2024 Omnicell Investment Highlights Omnicell is positioned as a leading strategic partner to health systems in the large and growing medication management market 30+ year track record of product innovation with a strong client base of more than one-half of the top 300
Slide 4: Our Strategy
Investor Relations – August 1, 2024 Our Strategy Omnicell is transforming pharmacy care through outcomes-centric innovation combining robotics, smart devices, intelligent software, and expert services designed to optimize clinical and business outcomes across all settings of care. H E ALT H S YS T E
Slide 5: Why We Believe Omnicell is Positioned to Win
Investor Relations – August 1, 2024 Why We Believe Omnicell is Positioned to Win Omnicell has the right Omnicell has a proven Omnicell is scaling Continued investment in solutions and the right track record of innovation Advanced Services to new products and business m odel to solve as the leading s
Slide 6: The Autonomous Pharmacy
Investor Relations – August 1, 2024 The Autonomous Pharmacy Industry-Defined Vision Replace manual, error-prone activities with automated processes that are designed to be safer and more efficient. o Zero medication errors o Zero medication waste o Zero human touches until delivery to patient o 100%
Slide 7: Delivering Solutions Designed to Support Customer Operational and Economic Environments
Investor Relations – August 1, 2024 Delivering Solutions Designed to Support Customer Operational and Economic Environments C H A LLE N G E O U T C O M E D E LIVE R E D Barcode scanning through Central 25,000 Errors Annually in Hospitals 1 100% Pharmacy robotics supports enhanced safety and accuracy
Slide 8: Revenue Growth Drivers
Investor Relations – August 1, 2024 Revenue Growth Drivers Deep Customer Relationships Multiple Growth Drivers & Robust Backlog o Expansion opportunities within o Strong position with more existing customer base than one-half of the top 300 U.S. health systems o Advanced Services expand our Total Ad
Slide 9: XT Amplify
XT Amplify Innovative solutions designed to maximize the value of XT technology © 2024 Omnicell, Inc. 9
Slide 10: XT Amplify
Investor Relations – August 1, 2024 XT Amplify Initial offerings in the multi-year XT Amplify innovation program XTExtend MedChill SupplyXpert ServerScale CarePlus © 2024 Omnicell, Inc. 10
Slide 11: Omnicell's Suite of Advanced Services
Investor Relations – August 1, 2024 Omnicell’s Suite of Advanced Services Varying combinations of robotics, smart devices, intelligent software, and expert services that are designed to deliver outcomes in each setting of care where medications are managed IV Compounding Central Pharmacy CarePlus In
Slide 12: Advanced Services Accelerating Recurring Revenue Growth
Investor Relations – August 1, 2024 Advanced Services Accelerating Advanced Services Potential Revenue Opportunity Recurring Revenue Growth o Leveraging established channels and strong customer relationships Advanced Services (% of Total Revenue) o Demand driven by increasing Targeting 21% of provid
Slide 13: Financial Snapshot
Investor Relations – August 1, 2024 Financial Snapshot Q2–2024 Results YoY Change % Total Revenues $277 Million -7% Non-GAAP Gross Margin % 44.2% -260 basis points Non-GAAP Operating Expenses $97 Million -10% Non-GAAP EBITDA $40 Million -15% Non-GAAP Diluted Earnings Per Share $0.51 -11% See Appendi
Slide 14: 2024 Guidance
Investor Relations – August 1, 2024 2024 Guidance Long-Term Value Creation Opportunities Q3–2024 TY–2024 o Leadership position in the digital transformation of healthcare Bookings1 Not guided $775 Million–$875 Million o Emerging and scaling of Advanced Total Revenues $275–$285 Million $1.070–$1.110
Slide 15: Total Year Revenue Composition
Investor Relations – August 1, 2024 Total Year Revenue Composition Recurring Year over Year Actual YoY Actual YoY Guidance GAAP ($Million) vs Non Category (YoY) TY– Change % TY–2022 Change % TY–2024 Recurring Change % 2023 (Mid-Point) Connected Devices, Software Licenses, Non 1 Product $828 12% $623
Slide 16: Backlog ($Million)
Investor Relations – August 1, 2024 Backlog1 ($Million) By Type As of December 31, 2023 As of December 31, 2022 Product Backlog $611 $797 Advanced Services Backlog2 $532 $418 Total Backlog $1,143 $1,215 By Duration and Type As of December 31, 2023 As of December 31, 2022 Short-Term Product Backlog $
Slide 17: Strong Balance Sheet
Investor Relations – August 1, 2024 Strong Balance Sheet $2,292M As Omnicell reinvests in the transformation to $1,203M Advanced Services, Free $1,016M Cash Flow is expected $557M $554M to slow $32M Liquidity and capital Cash and Cash Equivalents Total Assets Total Equity structure support 1.9x grow
Slide 18: A Better Way: ESG in Action
Investor Relations – August 1, 2024 A Better Way: ESG in Action 2023 Environment Social ESG Report o Decreased Scope 1 and 2 emissions in 2023 by o Amplified our charitable impact globally and almost 10% from 2022 increased employee engagement through Omnicell Published fourth annual o Strengthened
Slide 19: Appendix
Appendix
Slide 20: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Reconciliation of GAAP gross profit to non-GAAP gross profit: GAAP gross profit $ 114351 134443 $ 206974 $ 259,4
Slide 21: Tax effects footnote
(a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2024 and 2023. © 2024 Omnicell, Inc. 21
Slide 22: Reconciliation of GAAP to Non-GAAP
© 2024 Omnicell, Inc. Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited. in thousands, except per share data and percentage) Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - diluted: Shares - diluted GAAP ‘Shares - diluted non-GAAP GAAP net i
Slide 23: Reconciliation of GAAP to Non-GAAP
‘Ommnicell, Inc. Reconciliation of GAAP to Non-GAAP. (Wnandited, in thousands, except per share data and percentage) Three Months Ended Three Months Ended Three Months Ended Three Months Ended Year Ended June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023, December 31, 2017 Reconciliat
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) © 2024 Omnicell, Inc. 24
Slide 25: Slide 25